Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Continue

Publications

T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study

Angyal A. et al, (2021), The Lancet Microbe

The impact of viral mutations on recognition by SARS-CoV-2 specific T-cells.

de Silva TI. et al, (2021), iScience

Co-evolutionary signals identify Burkholderia pseudomallei survival strategies in a hostile environment.

Chewapreecha C. et al, (2021), Mol Biol Evol

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine.

Payne RP. et al, (2021), Cell

Durability of ChAdOx1 nCov-19 (AZD1222) vaccination in people living with HIV - responses to SARS-CoV-2, variants of concern and circulating coronaviruses

Ogbe A. et al, (2021)

Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients.

Youngs J. et al, (2021), PLoS Pathog, 17

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.

Skelly DT. et al, (2021), Nature communications, 12

Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern.

Skelly DT. et al, (2021), Nat Commun, 12

Effects of antibiotic resistance, drug target attainment, bacterial pathogenicity and virulence, and antibiotic access and affordability on outcomes in neonatal sepsis: an international microbiology and drug evaluation prospective substudy (BARNARDS).

Thomson KM. et al, (2021), Lancet Infect Dis

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum.

Liu C. et al, (2021), Cell, 184, 4220 - 4236.e13

Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.

Barrett JR. et al, (2021), Nat Med, 27

Author Correction: T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial.

Ewer KJ. et al, (2021), Nat Med

A blood atlas of COVID-19 defines hallmarks of disease severity and specificity

Ahern DJ. et al, (2021)

COVID-19 vaccine coverage in health-care workers in England and effectiveness of BNT162b2 mRNA vaccine against infection (SIREN): a prospective, multicentre, cohort study.

Hall VJ. et al, (2021), Lancet, 397, 1725 - 1735

T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses.

Ogbe A. et al, (2021), Nat Commun, 12

SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)

Hall VJ. et al, (2021), The Lancet

A haemagglutination test for rapid detection of antibodies to SARS-CoV-2.

Townsend A. et al, (2021), Nat Commun, 12

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Voysey M. et al, (2021), Lancet, 397, 881 - 891

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera.

Zhou D. et al, (2021), Cell

Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera.

Supasa P. et al, (2021), Cell

Load More

1
2
3
4
5
6